EMPAONE 25 TAB

Distributor inventory | Tablet

Treatment of type 2 diabetes mellitus to improve glycaemic control (along with diet and exercise); may also be used to reduce risk of cardiovascular events in eligible adults with type 2 diabetes as prescribed.

Empagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys. It increases urinary glucose excretion, thereby lowering blood sugar and causing mild diuresis.

Oral tablet. Take once daily as prescribed, preferably at the same time each day, with or without food. Maintain adequate hydration; follow diet/exercise advice and monitor blood glucose.

Increased urination,thirst,dehydration,dizziness,genital fungal infection (vaginal yeast infection/balanitis),urinary tract infection,nausea,itching

Not for type 1 diabetes or diabetic ketoacidosis. Risk of dehydration/low blood pressure (especially elderly, on diuretics), genital and urinary infections, and rare ketoacidosis even with normal sugars—seek medical help for nausea/vomiting, abdominal pain, rapid breathing. Stop and consult doctor if severe genital/perineal pain/swelling (possible Fournier’s gangrene). Use caution in kidney impairment; may need dose review/avoid in severe renal disease or dialysis. Monitor renal function and blood pressure; hypoglycaemia risk increases when combined with insulin/sulfonylureas.

Insulin and sulfonylureas (increased hypoglycaemia risk),diuretics (increased dehydration/hypotension risk),other antihypertensives (additive BP lowering),lithium (levels may decrease),alcohol/low-carb or fasting states (may increase ketoacidosis risk)

Store below 30°C in a cool, dry place. Protect from moisture and light. Keep out of reach of children.

Jardiance 25 mg Tablet,Glyxambi 25/5 mg Tablet (empagliflozin/linagliptin),Empagliflozin 25 mg Tablet (generic),Empa 25 Tablet (brand-dependent),Empagliflozin 25 mg (other brand equivalents)